Article
Chemistry, Medicinal
Xiao-Chong Li, Bang-Sheng Wu, Yi Jiang, Jie Li, Ze-Fen Wang, Chao Ma, Yi-Rong Li, Jie Yao, Xiao-Qing Jin, Zhi-Qiang Li
Summary: The study demonstrates that the development and progression of glioma alter the composition of gut microbiota. Treatment with temozolomide leads to an enrichment in Akkermansia and Bifidobacterium, as well as prevents the reduction of Anaerotruncus, contributing to its anti-tumor effect. This research helps to reveal the association between specific microbial species in the gut and the anti-tumor effect of temozolomide.
DRUG DESIGN DEVELOPMENT AND THERAPY
(2021)
Article
Oncology
Tadas K. Rimkus, Austin B. Arrigo, Dongqin Zhu, Richard L. Carpenter, Sherona Sirkisoon, Daniel Doheny, Angelina T. Regua, Grace L. Wong, Sara Manore, Calvin Wagner, Hui-Kuan Lin, Guangxu Jin, Jimmy Ruiz, Michael Chan, Waldemar Debinski, Hui-Wen Lo
Summary: The study found that TUSC2 protein expression is reduced in glioblastoma compared to normal brain due to protein destabilization. NEDD4-mediated polyubiquitination is a novel mechanism for TUSC2 degradation in glioblastoma. TUSC2 loss promotes glioblastoma progression through upregulation of Bcl-xL and its knockout gene signature predicts poor patient survival.
Article
Oncology
Quan Cheng, Anliu Tang, Zeyu Wang, Ning Fang, Zhuojing Zhang, Liyang Zhang, Chuntao Li, Yu Zeng
Summary: Caldesmon (CALD1) may play a crucial role in monitoring glioma patient prognosis and angiogenesis, with higher CALD1 expression associated with worse clinical outcomes and potential modulation of tumor angiogenesis. High CALD1 expression was also linked to abnormal microvessels in anaplastic astrocytoma and GBM, making CALD1 a possible key marker for monitoring glioma progress.
Review
Oncology
Maximilian J. Mair, Marjolein Geurts, Martin J. van den Bent, Anna S. Berghoff
Summary: WHO grade II-III gliomas are rare primary brain tumors with longer median survival compared to grade IV glioblastoma. Treatment involves maximal safe resection and adjuvant therapies, with challenges in conducting clinical trials due to rarity and long follow-up times. The 2016 WHO Classification introduced a molecular diagnostic framework for more homogenous subgroups. Available evidence for adjuvant treatment was generated pre-molecular era, emphasizing the need for further research in this field.
CANCER TREATMENT REVIEWS
(2021)
Article
Oncology
Sujie Gu, Zesheng Peng, Yuxi Wu, Yihao Wang, Deqiang Lei, Xiaobing Jiang, Hongyang Zhao, Peng Fu
Summary: Overexpression of COL5A1 in gliomas is associated with disease progression and poor prognosis, while downregulation can inhibit proliferation and migration of tumor cells and increase their sensitivity to temozolomide. Furthermore, genes co-expressed with COL5A1 participate in various pathways and biological processes involved in glioma progression. Additionally, dendritic cells in the tumor microenvironment of gliomas are positively correlated with the expression levels of COL5A1.
FRONTIERS IN ONCOLOGY
(2021)
Article
Medicine, General & Internal
Xu Wang, Yi Zhou, Yan Wang, Xiang Wang, Yu Zhang, Yufei Mao, Long Zhang, Ji Qi, Yining Zhang, Feng Lyu, Linbo Gu, Rutong Yu, Xiuping Zhou
Summary: SU4312 inhibits glioma progression by down-regulating YAP transcription and CCL2 secretion, and can enhance the antitumor effect of temozolomide.
JOURNAL OF CLINICAL MEDICINE
(2022)
Article
Oncology
Jonathan P. S. Knisely, Howard A. Fine
Summary: The Oncology Grand Rounds series aims to provide clinical context to original reports published in the Journal. It includes case presentations, discussions on diagnostic and management challenges, literature reviews, and suggested management approaches by the authors. The goal is to help readers apply key study findings, including those from the Journal of Clinical Oncology, to their own clinical practice.
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Review
Oncology
Yifan Ma, Yue Wang, Chen Nie, Yongzhong Lin
Summary: Through a comprehensive meta-analysis, this study found that targeted therapy combined with radiotherapy and chemotherapy can improve the survival rate and progression-free survival of glioma patients to some extent.
FRONTIERS IN ONCOLOGY
(2023)
Article
Oncology
Melodie Davy, Laurie Genest, Christophe Legrand, Oceane Pelouin, Guillaume Froget, Vincent Castagne, Tristan Rupp
Summary: Grade 4 gliomas and glioblastomas are the most common and aggressive brain tumors. Temozolomide, the current standard treatment, has varying responses depending on the tumor type, while Fingolimod, an immunomodulatory drug, may need further evaluation for its potential activity. The study highlights the need for new therapies to improve survival and quality of life for glioblastoma patients.
Article
Cell Biology
Simona Pellecchia, Marco De Martino, Francesco Esposito, Cristina Quintavalle, Alfredo Fusco, Pierlorenzo Pallante
Summary: GBM is classified into four subtypes based on molecular signature genes, with MPPED2 downregulation found in malignant neoplasias and being associated with poor prognosis. This study showed that restoring MPPED2 expression in GBM cell lines decreased cell growth, migration, and increased sensitivity to chemotherapy, suggesting a potential innovative therapy for GBM.
Article
Oncology
Zheng-Cheng Yu, Tianhe Li, Ellen Tully, Peng Huang, Chih-Ning Chen, Philipp Oberdoerffer, Stephanie Gaillard, Ie-Ming Shih, Tian-Li Wang
Summary: ARID1A is a subunit of SWI/SNF chromatin remodeling complexes and is frequently mutated in various types of human cancers, especially those originating from endometrial epithelium. Loss-of-function mutations in ARID1A affect epigenetic regulation, cell-cycle checkpoint control, and DNA damage repair. This study demonstrates that ARID1A-deficient cells harbor DNA base lesions and impaired base excision repair. Furthermore, the combination of temozolomide and PARP inhibitors effectively induces DNA damage and suppresses tumor growth in ARID1A-mutated cancers.
Article
Multidisciplinary Sciences
Mohammad Hazaymeh, Ronja Loeber-Handwerker, Katja Doering, Tammam Abboud, Dorothee Mielke, Veit Rohde, Vesna Malinova
Summary: Approximately 25% of glioblastomas show corpus callosum infiltration at diagnosis, which is associated with poor prognosis. The extent of corpus callosum involvement ranges from partial unilateral to complete bilateral infiltration. The role of surgery in glioblastoma with corpus callosum involvement is controversial.
SCIENTIFIC REPORTS
(2022)
Review
Clinical Neurology
Javier A. Jacobo, Sonia Mejia-Perez, Sergio Moreno-Jimenez
Summary: Neoadjuvant chemotherapy has been shown to be effective in improving surgical resection in low-grade gliomas, with limited evidence available for high-grade gliomas. It has played a role in overcoming barriers to greater extent of resection in patients with complex gliomas.
WORLD NEUROSURGERY
(2021)
Article
Chemistry, Multidisciplinary
Yan Zou, Yibin Wang, Sen Xu, Yanjie Liu, Jinlong Yin, David B. Lovejoy, Meng Zheng, Xing-Jie Liang, Jong Bae Park, Yuri M. Efremov, Ilya Ulasovand, Bingyang Shi
Summary: A new type of GBM-cell membrane camouflaged and pH-sensitive biomimetic nanoparticles have been developed for combined TMZ and CDDP therapy for GBM. The results show that these nanoparticles can efficiently transport drugs across the blood-brain barrier and specifically target GBM, allowing for controlled release at GBM sites and demonstrating potent anti-GBM effects without obvious side effects.
ADVANCED MATERIALS
(2022)
Article
Medicine, Research & Experimental
Kittikun Viwatpinyo, Sujira Mukda, Sakan Warinhomhoun
Summary: This study demonstrates that MG induces cell death and cell cycle arrest, disrupts cell migration, and reduces the clonogenicity of brain tumor cells.
BIOMEDICINE & PHARMACOTHERAPY
(2023)
Article
Cell Biology
Marco Fiorillo, Fanni Toth, Matteo Brindisi, Federica Sotgia, Michael P. Lisanti
Article
Cell Biology
Federica Sotgia, Michael P. Lisanti
Article
Oncology
Ke Chen, Xuanmao Jiao, Anthony Ashton, Agnese Di Rocco, Timothy G. Pestell, Yunguang Sun, Jun Zhao, Mathew C. Casimiro, Zhiping Li, Michael P. Lisanti, Peter A. McCue, Duanwen Shen, Samuel Achilefu, Hallgeir Rui, Richard G. Pestell
Article
Oncology
Bela Ozsvari, Luma G. Magalhaes, Joe Latimer, Jussi Kangasmetsa, Federica Sotgia, Michael P. Lisanti
FRONTIERS IN ONCOLOGY
(2020)
Article
Oncology
Rosa Sanchez-Alvarez, Ernestina Marianna De Francesco, Marco Fiorillo, Federica Sotgia, Michael P. Lisanti
FRONTIERS IN ONCOLOGY
(2020)
Review
Biochemistry & Molecular Biology
Francesca De Santis, Giovanni Fuca, Dirk Schadendorf, Alberto Mantovani, Luca Magnani, Michael Lisanti, Stephen Pettitt, Matteo Bellone, Giannino Del Sal, Saverio Minucci, Alexander Eggermont, Paolo Bruzzi, Silvio Bicciato, Pierfranco Conte, Roberta Noberini, John Hiscott, Filippo De Braud, Michele Del Vecchio, Massimo Di Nicola
Summary: Experts at the Tenth Edition of the Annual Congress on Anticancer Innovative Therapy shared the latest knowledge and novel therapeutic approaches in fields such as immuno-oncology, epigenetics, cancer metabolism, cancer stem cells, tumor cell signaling, and the immune system. The conference also discussed possible mechanisms of resistance to these innovative therapies, particularly with respect to immune checkpoint blockers (ICB), providing a broad overview of future challenges and hopes for improving cancer treatment in the medium-short term.
CYTOKINE & GROWTH FACTOR REVIEWS
(2021)
Article
Multidisciplinary Sciences
Cristian Scatena, Giovanni Fanelli, Giuseppe Nicolo Fanelli, Michele Menicagli, Paolo Aretini, Valerio Ortenzi, Sara Piera Civitelli, Lorenzo Innocenti, Federica Sotgia, Michael P. Lisanti, Antonio Giuseppe Naccarato
Summary: Recent evidence indicates that loss of caveolin expression in the stromal compartment of human invasive breast carcinoma may be predictive of disease recurrence, metastasis, and poor prognosis. Additionally, a study on sCav-1 expression in breast cancer and axillary lymph nodes suggests that the loss of Cav-1 in lymph nodes may contribute to metastatic spread in breast cancer.
SCIENTIFIC REPORTS
(2021)
Article
Biochemistry & Molecular Biology
Marco Fiorillo, Cristian Scatena, Antonio Giuseppe Naccarato, Federica Sotgia, Michael P. Lisanti
Summary: This study identifies high ATP production by the mitochondrial ATP-synthase as a new therapeutic target for anticancer therapy, particularly for inhibiting tumor progression. ATP-high cancer cells exhibit aggressive phenotypes with increased proliferation, stemness, anchorage-independence, cell migration, invasion, and multi-drug resistance, along with high antioxidant capacity. ATP depletion through targeting ATP5F1C may serve as a promising strategy for preventing metastasis and avoiding treatment failure, making ATP5F1C a potential biomarker and molecular target for future drug development to prevent metastatic disease progression.
CELL DEATH AND DIFFERENTIATION
(2021)
Article
Immunology
Jacqueline S. Eacret, Elizabeth M. Parzych, Donna M. Gonzales, James M. Burns
Summary: The use of PfMSP8 as a carrier to optimize a PfMSP2-based subunit malaria vaccine showed promising results in terms of antibody production and T cell recognition. The choice of adjuvant impacted the specificity and functionality of induced antibodies.
JOURNAL OF IMMUNOLOGY
(2021)
Article
Oncology
Camillo Sargiacomo, Sophie Stonehouse, Zahra Moftakhar, Federica Sotgia, Michael P. Lisanti
Summary: MTDR can be used to target and eradicate cancer stem cells by selectively interfering with mitochondrial metabolism in breast cancer cells. It significantly inhibits tumor growth and metastasis with little to no toxicity observed in a preclinical animal model.
FRONTIERS IN ONCOLOGY
(2021)
Article
Cell Biology
Filippo Di Pisa, Elisa Pesenti, Maria Bono, Andrea N. Mazzarello, Cinzia Bernardi, Michael P. Lisanti, Giovanni Renzone, Andrea Scaloni, Ermanno Ciccone, Franco Fais, Silvia Bruno, Paolo Scartezzini, Fabio Ghiotto
Summary: This study sheds light on the potential role of SH3BGRL3 in regulating myosin-cytoskeleton interaction and cell migration. It was found that SH3BGRL3 specifically interacts with Myo1c in a Ca2+-dependent manner, suggesting a potential regulatory mechanism for cytoskeleton dynamics involving SH3BGRL3 and Myo1c.
BMC MOLECULAR AND CELL BIOLOGY
(2021)
Review
Oncology
Marco Fiorillo, Bela Ozsvari, Federica Sotgia, Michael P. Lisanti
Summary: The study suggests that high mitochondrial ATP production is a new therapeutic target for cancer treatment, isolating metabolically fit cancer cells with enhanced stem-like properties and invasive abilities. By regulating mitochondrial ATP-synthase, prevention of metastasis in cancer cells is possible.
FRONTIERS IN ONCOLOGY
(2021)
Article
Biochemistry & Molecular Biology
Matteo Brindisi, Luca Frattaruolo, Marco Fiorillo, Vincenza Dolce, Federica Sotgia, Michael P. Lisanti, Anna Rita Cappello
Summary: This study found that elevated cholesterol levels increase the aggressiveness of breast cancer cells and promote the release of pro-inflammatory factors. Furthermore, there is a close symbiotic relationship between breast cancer cells and the microenvironment. These findings highlight the potential of targeting the cholesterol-ERR alpha synergy for breast cancer treatment.
Article
Cell Biology
Nils Wellhausen, Ryan P. O'Connell, Stefanie Lesch, Nils W. Engel, Austin K. Rennels, Donna Gonzales, Friederike Herbst, Regina M. Young, K. Christopher Garcia, David Weiner, Carl H. June, Saar I. Gill
Summary: This study aims to develop a universal CAR T cell therapy targeting the pan-leukocyte marker CD45. By editing the epitope on CD45, healthy hematopoietic cells can be protected from CAR T cell toxicity while maintaining the essential functions of CD45. This therapy demonstrates efficacy against multiple blood cancers and shows good tolerability and effectiveness in experiments. Additionally, edited hematopoietic stem cells can engraft and differentiate in vivo.
SCIENCE TRANSLATIONAL MEDICINE
(2023)
Article
Cell Biology
Sundee Dees, Laura Pontiggia, Jean-Francois Jasmin, Federica Sotgia, Michael P. Lisanti, Isabelle Mercier